Related Experiment Videos
Oligonucleotide-based gene therapy for cardiovascular disease
R Morishita1, H Nakagami, Y Taniyama
1Department of Geriatric Medicine, Osaka University Medical School, Suita, Japan.
Insights
Oligonucleotide-based gene therapy offers a promising new avenue for treating cardiovascular diseases like restenosis and familial hypercholesterolemia, addressing conditions with limited effective treatments. This approach leverages advancements in gene transfer technology for in vivo applications.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Gene Therapy
Background:
- Cardiovascular diseases (CVDs) such as restenosis, graft occlusion, and familial hypercholesterolemia lack effective therapeutic options.
- Gene therapy presents a potential strategy for treating these challenging cardiovascular conditions.
- Efficient in vivo gene transfer is crucial for the success of gene therapy in cardiovascular applications.
Purpose of the Study:
- To review the future potential of oligonucleotide-based gene therapy for cardiovascular disease management.
- To highlight the emergence of gene therapy as a viable treatment strategy for specific cardiovascular disorders.
Main Methods:
- Review of existing literature on gene transfer technologies, including viral methods.
- Analysis of the molecular biology and pathophysiology of the cardiovascular system.
- Focus on oligonucleotide-based approaches for in vivo gene transfer.
Main Results:
- Numerous gene transfer methods, including viral techniques, have been developed over the past decade.
- Some gene transfer methods are currently being utilized in clinical human gene therapy studies.
- The convergence of molecular cardiovascular biology and pathophysiology supports the introduction of gene therapy.
Conclusions:
- Oligonucleotide-based gene therapy holds significant future potential for treating cardiovascular diseases.
- Gene therapy is poised to become an important tool in managing cardiovascular disorders, especially those with unmet therapeutic needs.
Abstract:
Gene therapy is emerging as a potential strategy for the treatment of cardiovascular disease such as restenosis after angioplasty, vascular bypass graft occlusion, transplant coronary vasculopathy, homozygous familial hypercholesterolemia and cystic fibrosis, for which no known effective therapy exists. Gene therapy requires efficient in vivo gene transfer technology. During the past decade, many gene transfer methods including viral transfer techniques have been developed, and some are being applied clinically in human gene therapy studies. Molecular biology and pathophysiology of the cardiovascular system have started to emerge, and the time is ripe for the introduction of gene therapy to the management of cardiovascular disorders. In this review, we have focused on the future potential of oligonucleotide-based gene therapy for the treatment of cardiovascular disease.